The company has reached profitability and blockbuster sales status, with strong patient growth and market expansion. Key catalysts to watch: MAESTRO-CSPH trial initiation in H1 2027, MAESTRO-NASH OUTCOMES data in late 2027, and continued quarterly revenue growth trajectory.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 3 $396.32entry
- T+1 · yesterday +1.04%α −0.61% · $400.43
- T+2 · todayOpen
- T+5 · in 5d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Madrigal Pharmaceuticals reported Q3 2026 Rezdiffra net sales of $431.3M, a 50% YoY increase, and achieved its first profitable quarter with net income of $55.4M ($1.83 diluted EPS) versus a $114.2M loss a year ago. The company also announced a new Phase 3 MAESTRO-CSPH trial for compensated MASH cirrhosis (F4c) expected to start in H1 2027.
Key Financial Metrics
Key Facts
- Q3 2026 Rezdiffra net sales $431.3M, up 50% YoY from $287.3M
- First profitable quarter: net income $55.4M ($1.83 diluted EPS) vs net loss $114.2M ($4.01 loss per share) in Q3 2025
- Year-to-date Rezdiffra net sales $1.1B, achieving blockbuster status
- Over 55,850 patients on Rezdiffra as of Sept. 30, 2026, nearly double Q3 2025
- U.S. F2-F3 MASH addressable market >530,000 patients, on track for >30% growth by YE26
- New Phase 3 MAESTRO-CSPH outcomes trial for F4c cirrhosis planned, enrollment >2,000 patients, initiation H1 2027
- Cash and securities $961.8M as of Sept. 30, 2026
- EPS of $1.83 diluted beat consensus estimate of ($1.09) by 267.9%
Financial Impact
Q3 revenue of $431.3M exceeded consensus of $405.1M by 6.5%; EPS of $1.83 diluted versus consensus ($1.09) represents a $2.92 positive surprise. First profitable quarter marks a fundamental shift from prior losses.
Risk Factors
- Competition from other MASH therapies in development could pressure Rezdiffra market share
- Regulatory and enrollment risks for the new F4c cirrhosis trial
- SG&A expenses rising 27% YoY as commercial investment continues
- Dependence on single product Rezdiffra for all revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3394036 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 5, 2026 today | Press Release | $398.18 | awaiting T+1 | awaiting T+1 | $399.90 (+0.43%) |
Nov 3, 2026 2d ago | 8-K | No price | awaiting T+1 | awaiting T+1 | No price |
Nov 3, 2026 2d ago | Press Release | $396.32 $400.43 | ▲ +1.04% | ▼ −0.61% | $399.90 (+0.90%) |
Aug 12, 2026 12w ago | 8-K | $536.20 $507.37 | ▼ −5.38% | ▼ −6.07% | $399.90 (−25.42%) |
Jul 30, 2026 14w ago | 8-K | $493.11 $467.32 | ▼ −5.23% | ▼ −5.94% | $399.90 (−18.90%) |
May 22, 2026 23w ago | Insider Cluster | $524.28 $527.67 | ▲ +0.65% | ▲ +0.63% | $399.90 (−23.72%) |
May 6, 2026 26w ago | 8-K | $539.73 $534.86 | ▼ −0.90% | ▼ −0.57% | $399.90 (−25.91%) |
Apr 28, 2026 27w ago | 8-K | $518.58 $517.39 | ▼ −0.23% | ▼ −1.25% | $399.90 (−22.89%) |
Apr 22, 2026 28w ago | Press Release | $529.14 $518.74 | ▼ −1.97% | ▼ −1.57% | $399.90 (−24.42%) |
Mar 19, 2026 32w ago | Press Release | $441.16 $447.72 | ▲ +1.49% | ▲ +0.38% | $399.90 (−9.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers